Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b63e00734c7dae2e2dccd070bb2c62cb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2016-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14be20c6cb37e7a65c2335f1ee79ddcd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2015b5ffb402b2146dc8b1713d30f1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b585007a5f9bc7e95f34cf40eac7fb69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d9a02ccc3cbfc939066f7f2e1c9a082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e2cc3008bfdb5ff40128e01553d3fb3 |
publicationDate |
2016-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2016203408-A1 |
titleOfInvention |
Folate Receptor Alpha as a Diagnostic and Prognostic Marker for Folate Receptor Alpha-Expressing Cancers |
abstract |
Abstract Folate Receptor Alpha As A Diagnostic And Prognostic Marker for Folate Receptor Alpha-Expressing Cancers The present invention provides methods and kits for assessing whether a subject is afflicted with an FRa-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FRa-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FRa-expressing cancer, and methods of stratifying a subject with an FRa-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FRa) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FRa in a control sample. |
priorityDate |
2010-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |